RedHill Biopharma Ltd - Company Profile (NASDAQ:RDHL)

Analyst Ratings

Consensus Ratings for RedHill Biopharma Ltd - (NASDAQ:RDHL) (?)
Ratings Breakdown: 6 Buy Rating(s)
Consensus Rating:Buy (Score: 3.00)
Consensus Price Target: $28.83 (137.51% upside)

Analysts' Ratings History for RedHill Biopharma Ltd - (NASDAQ:RDHL)
Show:
DateFirmActionRatingPrice TargetActions
5/3/2016FBR & CoReiterated RatingBuyView Rating Details  Tweet This Rating  Share This Rating on StockTwits
3/29/2016Nomura Holdings Inc.Reiterated RatingBuyView Rating Details  Tweet This Rating  Share This Rating on StockTwits
2/28/2016HC WainwrightReiterated RatingBuy$33.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
2/27/2016Roth CapitalReiterated RatingBuyView Rating Details  Tweet This Rating  Share This Rating on StockTwits
11/11/2015Ascendiant Capital MarketsLower Price TargetBuy$28.00 -> $26.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
9/29/2015Northland SecuritiesInitiated CoverageBuy$25.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
7/2/2015MLV & Co.Initiated CoverageBuy$33.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
(Data available from 7/24/2014 forward)

Earnings

Earnings History for RedHill Biopharma Ltd - (NASDAQ:RDHL)
DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallActions
4/20/2016Q1($0.48)$0.04ViewListenView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
11/9/2015Q315($0.51)($0.04)ViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
7/29/2015Q215($0.49)($0.07)ViewListenView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
4/30/2015Q115($0.56)($0.50)ViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
2/26/2015Q414($0.60)$0.06ViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
11/10/2014($0.61)($0.50)ViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
7/24/2014($0.38)($0.52)ViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
6/6/2014($0.44)$0.39ViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
4/30/2014($0.44)$0.39ViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
11/12/2013Q3 13($0.62)($0.04)ViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
(Data available from 1/1/2011 forward)

Estimates

Earnings Estimates for RedHill Biopharma Ltd - (NASDAQ:RDHL)
QuarterNumber of EstimatesLow EstimateHigh EstimateAverage Estimate
Q1 20161($0.49)($0.49)($0.49)
Q2 20161($0.54)($0.54)($0.54)
Q3 20162($0.59)($0.53)($0.56)
Q4 20162($0.63)($0.34)($0.49)
(Data provided by Zacks Investment Research)

Dividends

Dividend History for RedHill Biopharma Ltd - (NASDAQ:RDHL)
No dividend announcements for this company have been tracked by MarketBeat.com

Insider Trades

Insider Trading History for RedHill Biopharma Ltd - (NASDAQ:RDHL)
No insider trades for this company have been tracked by MarketBeat.com

Headlines

Latest Headlines for RedHill Biopharma Ltd - (NASDAQ:RDHL)
DateHeadline
07/23/16 05:33 PMRedHill Biopharma : Receives Additional U.S. Patent Covering RHB-105 Ahead of Confirmatory Phase III Study for H. pylori Infection
07/22/16 05:54 PMRedHill Biopharma (RDHL) Receives Additional USPTO Notice of Allowance for Patent Covering RHB-105
07/22/16 09:00 AMRedhill Biopharma Limited Ads (NASDAQ:RDHL) Shorted Shares Increased By 14.9% - Consumer Eagle
07/21/16 08:56 AMEquity Roundup: Stock Performance Focus on Redhill Biopharma Ltd. (NASDAQ:RDHL) - Press Telegraph
07/21/16 08:56 AMRedHill Biopharma (RDHL) Receives Additional USPTO Notice of Allowance for Patent Covering RHB-105 - StreetInsider.com
07/21/16 08:03 AMRedHill Biopharma Receives Additional U.S. Patent Covering RHB-105 Ahead of Confirmatory Phase III Study for H. pylori Infection - [GlobeNewswire] - RedHill has received a Notice of Allowance for an additional U.S. patent covering RHB-105, expected to be valid until 2034 once granted The planned confirmatory Phase III study with RHB-105 for the treatment ...
07/19/16 06:11 PMRedHill Biopharma to Host Second Quarter 2016 Financial Results Conference Call on July 26, 2016 - P&T Community
07/19/16 07:02 AMRedHill Biopharma to Host Second Quarter 2016 Financial Results Conference Call on July 26, 2016 - GlobeNewswire (press release)
07/19/16 07:02 AMRedhill Biopharma Limited Ads (NASDAQ:RDHL) Sellers Increased By 1.79% Their Shorts - Consumer Eagle
07/19/16 06:00 AMRedHill Biopharma to Host Second Quarter 2016 Financial Results Conference Call on July 26, 2016 - [GlobeNewswire] - TEL-AVIV, Israel, July 19, 2016-- RedHill Biopharma Ltd., a biopharmaceutical company primarily focused on development and commercialization of late clinical-stage, proprietary, orally-administered, small ...
07/18/16 11:34 AMRedHill Biopharma Ltd.: RedHill Biopharma and IntelGenx Announce Definitive Agreement for Commercialization of RIZAPORT(TM) for M.
07/16/16 09:19 AMAnalyst Target and Average Rating Watch: Redhill Biopharma Ltd. (NASDAQ:RDHL) - Press Telegraph
07/16/16 09:19 AMRedhill Biopharma Ltd. (RDHL) Updated Price Targets - FTSE News
07/15/16 11:13 AMRosario capital sees RedHill breakthrough
07/14/16 06:18 PMTrading Performance and Target Watch for Redhill Biopharma Ltd. (NASDAQ:RDHL) - Press Telegraph
07/13/16 06:27 PMRedhill Biopharma Ltd. (NASDAQ:RDHL) Wall Street Analyst Recommendation Outlook - Telanagana Press
07/13/16 06:27 PMHow Many RedHill Biopharma Ltd - ADR (NASDAQ:RDHL)'s Analysts Are Bearish? - Consumer Eagle
07/13/16 06:27 PMRedHill Biopharma (RDHL), NIH Enter Research Collaboration Covering Ebola Virus Therapy - StreetInsider.com
07/13/16 06:01 AM7:01 am RedHill Biopharma signs research collaboration agreement with the U.S. NIH intended to evaluate its proprietary experimental therapy for the treatment of Ebola virus disease -
07/13/16 06:00 AMRedHill Biopharma Announces Research Collaboration with NIH for Potential Ebola Treatment - [GlobeNewswire] - TEL-AVIV, Israel, July 13, 2016-- RedHill Biopharma Ltd., a biopharmaceutical company primarily focused on development and commercialization of late clinical-stage, proprietary, orally-administered, small ...
07/10/16 05:22 PMMori Arkin buys Redhill Biopharma stake - Globes
07/10/16 05:22 PMRedhill Biopharma Ltd. (RDHL) Broker Price Targets For The Coming Week - Fiscal Standard
07/08/16 08:57 AMCompany Stock Focus for Redhill Biopharma Ltd. (NASDAQ:RDHL): Which Way Will Shares Head? - Press Telegraph
07/08/16 08:57 AMRedhill Biopharma Ltd. (RDHL) Current Analyst Ratings - Fiscal Standard
07/07/16 06:08 PMCan Redhill Biopharma Ltd. (NASDAQ:RDHL) Improve on the Earnings Front? - Engelwood Daily
07/07/16 06:08 PMRedhill Biopharma Limited Ads (NASDAQ:RDHL) Short Interest Increased By 1.79% - Engelwood Daily
07/07/16 06:08 PMPerformance Recap and Target Perspective on Redhill Biopharma Ltd. (NASDAQ:RDHL) - Press Telegraph
07/06/16 06:21 PMRedhill Biopharma Ltd. (NASDAQ:RDHL) Stock Update: Check on Ratings and Target Price - Telanagana Press
07/05/16 05:50 PMRedHill Biopharma Ltd , IL0011223810
07/05/16 10:30 AMAre Analysts Bullish RedHill Biopharma Ltd – ADR (NASDAQ:RDHL) After Last Week? - Press Telegraph
07/05/16 10:30 AMRedHill Biopharma (RDHL), IntelGenx Enter Agreement for RIZAPORT Commercialization - StreetInsider.com
07/04/16 05:14 PMRedHill Biopharma Ltd.: RedHill Biopharma Announces Positive Final Results with Primary and Secondary Endpoints ... - Yahoo Finance UK
07/04/16 05:14 PMBroker Outlook For The Week Ahead Redhill Biopharma Ltd. (RDHL) - Fiscal Standard
06/30/16 08:52 AMAre Analysts Bearish RedHill Biopharma Ltd - ADR (NASDAQ:RDHL) After Last Week? - Press Telegraph
06/30/16 08:52 AMRedhill Biopharma Ltd. (NASDAQ:RDHL) Company Rating and Target Watch - Telanagana Press
06/25/16 09:47 AMCovering the Bases on Redhill Biopharma Ltd. (NASDAQ:RDHL): Where is the Stock Going? - Press Telegraph
06/25/16 09:47 AMRedhill Biopharma Ltd. (NASDAQ:RDHL) Earnings Glance and Target Price Review - Engelwood Daily
06/25/16 09:47 AMRedhill Biopharma Limited Ads (NASDAQ:RDHL) Shorted Shares Decreased By 15.1% - Press Telegraph
06/23/16 06:40 PMRedHill Biopharma Announces First Patients Dosed in Phase II Study with BEKINDA(TM) for IBS-D
06/23/16 06:40 PMDGAP-News: RedHill Biopharma Announces First Patients Dosed in Phase II Study with BEKINDA(TM) for IBS-D
06/23/16 08:45 AMEquity Research and Technical Review on Redhill Biopharma Ltd. (NASDAQ:RDHL) - Press Telegraph
06/22/16 06:01 PMRedHill Biopharma Announces Publication Demonstrating Potential Efficacy of RHB-104 for Crohn's Disease Associated with MAP Infection
06/22/16 06:01 PMREDHILL BIOPHARMA LTD ADR
06/22/16 06:01 PMRedHill Biopharma (RDHL) Announces YELIVA Phase 1 Met All Primary Objectives in Adv. Solid Tumors
06/22/16 10:48 AMRedHill Biopharma (RDHL) RHB-104 Potential Efficacy Highlighted in Publication - StreetInsider.com
06/22/16 09:11 AMRedHill (RDHL) Stock Up on Positive Phase I Data on Yeliva -
06/21/16 05:37 PMRedHill Biopharma Announces Positive Final Results with Primary and Secondary Endpoints Met in Phase 1 Study with YELIVA(TM) in Advanced Solid Tumors
06/21/16 05:37 PMRedHill Meets Goals In Phase 1 Study With YELIVA In Advanced Solid Tumors
06/21/16 10:24 AMRedHill Biopharma (RDHL) Announces YELIVA Phase 1 Met All Primary Objectives in Adv. Solid Tumors - StreetInsider.com
06/21/16 08:24 AMRedHill Biopharma Announces Positive Final Results with Primary and Secondary Endpoints Met in Phase 1 Study with YELIVA™ in Advanced Solid Tumors - [GlobeNewswire] - Final results from the Phase I study with YELIVA™ in patients with advanced solid tumors confirmed that the study, conducted at the Medical University of South Carolina, successfully met its primary and ...

Social

About RedHill Biopharma Ltd -

RedHill Biopharma Ltd - logoRedHill Biopharma Ltd. is a biopharmaceutical company primarily focused on the development of late clinical-stage, orally-administered, small molecule drugs for the treatment of inflammatory and gastrointestinal diseases, including gastrointestinal cancers. The Company's pipeline of products includes RHB-105, RHB-104, BEKINDA (RHB-102), RHB-106, ABC294640, MESUPRON, RP101 and RIZAPORT (RHB-103).

Industry, Sector and Symbol:
  • Sector: Medical
  • Industry: Biotechnology
  • Sub-Industry: N/A
  • Exchange: NASDAQ
  • Symbol: RDHL
  • CUSIP:
Key Metrics:
  • Previous Close: $11.75
  • 50 Day Moving Average: $10.94
  • 200 Day Moving Average: $11.07
  • P/E Ratio: N/A
  • P/E Growth: 0.00
  • Market Cap: $154.32M
  • Beta: 0.44
  • Current Year EPS Consensus Estimate: $-1.85 EPS
  • Next Year EPS Consensus Estimate: $-0.77 EPS
Additional Links:
RedHill Biopharma Ltd - (NASDAQ:RDHL) Chart for Sunday, July, 24, 2016